Author: Sorting Last Post on Top ↓ Message:
PHEBESS's Photo PHEBESS Posts: 41,238
9/26/13 2:10 A

Community Team Member

My SparkPage
Send Private Message
VEry good news!!!

"Dance as if no one is watching."

 Pounds lost: 45.0 
TWEETYKC00's Photo TWEETYKC00 Posts: 132,566
9/25/13 6:04 P

My SparkPage
Send Private Message
That can make a major difference, especially since it is such a long term med.

 Pounds lost: 104.7 
9/25/13 2:13 P

Send Private Message
New tenofovir has lower dose, is kinder to kidneys and bones.

September 23, 2013

New Tenofovir Has Lower Dose, Is Kinder to Kidneys and Bones

A new formulation of the widely used HIV antiretroviral tenofovir is potent at a lower dose and works as well as the current version of the drugóbut it has fewer effects on indicators of kidney and bone health, aidsmap reports. Paul Edward Sax, MD, clinical director at Brigham and Womenís Hospital and a professor of medicine at Harvard Medical School, presented findings from a Phase II study comparing Gilead Sciencesí new tenofovir alafenamide (TAF) with tenofovir disoproxil fumarate (TDF), which is the sole ingredient in Viread and a component of the single-pill combination therapies Truvada, Atripla, Complera and Stribild.

Researchers have found that concentrations of TAF in HIV-infected cells are five times higher than those of TDF. The new formulationís levels in blood are far lower by comparison, which would likely make TAF less toxic to the kidneys and bones.

In a double-blind, placebo-controlled study, the researchers divided 170 treatment naive people with HIV into groups with a ratio of two to one receiving either 10 milligrams of TAF or 300 mg of TDF once a day in a coformulated pill with elvitegravir, cobicistat and emtricitabine (which in the TDF arm meant the participants were taking Stribild) for 48 weeks.

At the studyís outset, the median viral load was about 40,000 and the median CD4 cell level was approximately 390. The participants had normal kidney function.

At the end of the 48 weeks, 88.4 percent of those taking the TAF coformulation had achieved an undetectable viral load, compared with 87.9 percent in the TDF group. Average CD4 gains between the two groups were a respective 177 and 204. None of these differences between the arms were statistically significant, meaning they could have happened by chance.

Indicators of kidney function, such as changes in a marker known as eGFR, evidence of protein in the urine and a shift in serum creatinine, suggested TAF is a safer drug. Similarly, indications of bone health, including DEXA scans taken at the spine and hip at 24 and 48 weeks to measure bone mineral density, showed less deterioration in the TAF group than in the TDF arm. A third of those taking TAF had no change in their hip bone density compared with 7 percent of the TDF group.

"How far that little candle throws its beams! So shines a good deed in a naughty world."
~William Shakespeare


Total SparkPoints: 98,561
SparkPoints Level 19
Page: 1 of (1)  

Report Innappropriate Post

Other Positive Positives HIV / AIDS and Our Supporters General Team Discussion Forum Posts

Topics: Last Post:
Moments of Stillness 9/20/2017 2:29:00 AM
I'm having a party and you're invited! 8/3/2017 1:43:32 AM
Aging with HIV: Struggle, Self-Love & Survival 9/22/2017 6:13:12 PM
HIV Advocacy in the Age of Trump 1/25/2017 8:14:27 PM
1 in 4 Smokers on effective HIV Treatment will Die 9/20/2017 4:26:54 PM

Thread URL:

Review our Community Guidelines